

PRESS RELEASE FROM FUTURE SCIENCE GROUP

December 2012

Contact: Victoria Lane, Senior Editor, Future Science Group

Tel: +44 (0) 20 8371 6090

Email: v.lane@future-science.com

***Future Medicinal Chemistry* continues its commitment to neglected diseases with special focus issue on malaria**

Guest edited by Jeremy Burrows (Head of Discovery, Medicines for Malaria Venture), the December issue (volume 4 issue 18) of *Future Medicinal Chemistry* is dedicated to the topic of antimalarial drug discovery. This follows the success of previous special issues covering advances in the area of neglected diseases. The issue will be free-to-access until March 2012.

“Interest in malaria drug research has undergone radical renewal in the past decade,” said Dr Burrows. “The disease places an unacceptably huge burden on vulnerable populations around the world. It is clear that new tools to control and eliminate this fatal disease are urgently needed. This issue of *Future Medicinal Chemistry* reflects this urgency and brings to light a broad spectrum of exciting research focused on malaria.”

Experts in the field from academia, industry and nonprofit organizations contributed to the special issue, which includes research articles, perspectives, special reports and reviews.

The issue opens with the Guest Editor’s foreword in which Dr Burrows states that the renaissance in antimalarial drug discovery is underway and expresses how sustained efforts on discovering, developing and delivering new, high-quality antimalarials for those in the poorest areas of the world are required.

A preliminary communication from Adam Renslo (University of California, San Francisco, CA, USA) and colleagues describes orthogonal experimental approaches to ferrous-iron dependent drug delivery from a prototypical fragmenting hybrid. There are reviews on the recent developments of 4(1*H*)-pyridones and aminothiazole compounds, as well as how diversity-oriented synthesis is being applied to the field. Although the development of antimalarial compounds for patients who have contracted the disease is still vitally important, there is a growing appreciation that malaria eradication will require novel interventions to target the parasite during transmission as highlighted by the perspective by Michael Delves (Imperial College, London, UK), and Vicky Avery and Leonardo Lucantoni’s review (Griffith University, Australia).

All articles from this issue will be **free to access** until the end of March 2013 from the journal’s website (<http://www.future-science.com/toc/fmc/4/18>).

Contributing authors include:

Jeremy Burrows (Medicines for Malaria Venture), Vicky Avery (Griffith University, Australia), Kelly Chibale (University of Cape Town, South Africa), Michael Delves (Imperial College, London, UK), José-Maria Bueno (GlaxoSmithKline, Tres Cantos Medicines Development Campus, Spain), Adam Renslo (University of California, San Francisco, CA, USA), Christian Doerig (Monash University, Australia), Benito Munoz (Broad Institute, MA, USA).

- - - ENDS - - -

ABOUT FUTURE MEDICINAL CHEMISTRY

Future Medicinal Chemistry provides a monthly platform (18 issues annually) for reviews and original research for the ever-expanding and diversifying pharmaceutical chemistry community, by showcasing milestones in R&D and featuring expert analysis of emerging developments. The journal is supported by an international Editorial Board headed by Professor Iwao Ojima (State University of New York at Stony Brook, USA) and Professor David Thurston (King's College London, UK). The journal is indexed by Medline®/Pubmed, ISI and other major services, and was granted its second impact factor of 2.522 in June 2012. The full Aims & Scope, along with the editorial structure, can be found on the journal's [web page](#).

ABOUT FUTURE SCIENCE GROUP

The Future Science Group (www.future-science-group.com) is a leading provider of products and services for the medical, science and business communities. The group is comprised by three independent publishing companies active at the forefront of scientific information, including Expert Reviews Ltd, Future Medicine Ltd and Future Science Ltd. Complete listings of titles available under each imprint are available at www.expert-reviews.com, www.futuremedicine.com and www.future-science.com.